Thromb Haemost 1995; 73(02): 203-209
DOI: 10.1055/s-0038-1653751
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Prothrombin Frankfurt: A Dysfunctional Prothrombin Characterized by Substitution of Glu-466 by Ala

Sandra J Friezner Degen
The Children’s Hospital Research Foundation and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
,
Susan A McDowell
The Children’s Hospital Research Foundation and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
,
Leah M Sparks
The Children’s Hospital Research Foundation and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
,
Inge Scharrer
1   The University Hospital Center of Internal Medicine, Frankfurt am Main, Germany
› Author Affiliations
Further Information

Publication History

Received 06 June 1994

Accepted after resubmission 07 October 1994

Publication Date:
26 July 2018 (online)

Summary

We have identified a patient with a dysfunctional prothrombin that we have designated Prothrombin Frankfurt. The proband was characterized by a prothrombin activity level of 13% and 20% compared to normal controls using two different assays with a normal prothrombin antigen level of 91% of normal controls. The genetic defect responsible for the abnormal prothrombin activity was determined by the polymerase chain reaction followed by single-strand conformation polymorphism (PCR-SSCP) analysis and by DNA sequence analysis of the human prothrombin gene. Substitution of a C for an A at nucleotide 10177 in the human prothrombin gene of the proband was identified, which results in the replacement of Glu-466 by Ala. The proband and one sister were homozygous for this mutation. Both parents, as well as one brother, were found to be heterozygous for this mutation. The same amino acid substitution was previously identified to be responsible for the dysfunctional protein Prothrombin Salakta and was hypothesized to result in altered substrate specificity. Four polymorphisms were also identified in the prothrombin gene from the proband when compared to the published sequence at nucleotides 554, 4048, 4272 and 10253.

 
  • References

  • 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370
  • 2 Davey MG, Luscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1997; 216: 857-858
  • 3 Chen L, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin Proc Natl Acad Sci USA 1995; 72: 131-135
  • 4 Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 1996; 83: 976-980
  • 5 Cunningham DD, Farrell DH. Thrombin interactions with cultured fibroblasts: relationship to mitogenic stimulation. Ann NY Acad Sci 1996; 485: 240-248
  • 6 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
  • 7 Degen SJ F. Prothrombin. In: Molecular Biology of Thrombosis and Hemostasis. Roberts H, High K. eds. Marcel Dekker, Inc.; New York: 1995. pp 75-99
  • 8 Magnusson S, Petersen TE, Sottrup-Jensen L, Claeys H. Complete primary structure of prothrombin: isolation, structure and reactivity of ten carboxy-lated glutamic acid residues and regulation of prothrombin activation by thrombin. In: Proteases and Biological Control. Reich E, Rifkin DB, Shaw E. eds. Cold Spring Harbor Laboratories; Cold Spring Harbor, NY: 1975. pp 123-149
  • 9 Butkowski RJ, Elion J, Downing MR, Mann KG. Primary structure of human prethrombin 2 and α-thrombin. J Biol Chem 1997; 252: 4942-4957
  • 10 Thompson AR, Enfield DL, Ericsson LH, Legaz ME, Fenton JW. Human thrombin: Partial primary structure. Arch Biochem Biophys 1997; 178: 356-367
  • 11 Walz DA, Hewett-Emmett D, Seegers WH. Amino acid sequence of human prothrombin fragments 1 and 2. Proc Natl Acad Sci USA 1997; 74: 1969-1972
  • 12 Seegers WH. Prothrombin yesterday and today. Prog Chem Fibrinolysis Thromb 1999; 4: 241-254
  • 13 Degen SJ F, MacGillivray RT A, Davie EW. Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry 1993; 22: 2087-2097
  • 14 Degen SJ F, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry 1997; 26: 6165-6177
  • 15 Henriksen RA, Mann KG. Identification of the primary structural defect in the dysthrombin thrombin Quick I: Substitution of cysteine for arginine-382. Biochemistry 1998; 27: 9160-9165
  • 16 Henriksen RA, Mann KG. Substitution of Val for Gly-558 in the congenital dysthrombin, thrombin Quick II, alters primary substrate specificity. Biochemistry 1999; 28: 2078-2082
  • 17 Rabiet M-J, Furie BC, Furie B. Molecular defect of prothrombin Barcelona. J Biol Chem 1996; 261: 15045-15048
  • 18 Diuguid D, Rabiet MJ, Furie BC, Furie B. Molecular defects of factor IX Chicago-2 (Arg 145 - His) and prothrombin Madrid (Arg 271 - Cys): arginine mutations that preclude zymogen activation. Blood 1999; 74: 193-200
  • 19 Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin M-C, Iwanaga S. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry 1992; 31: 7457-7462
  • 20 Morishita E, Saito M, Kumabashiri I, Asakura H, Matsuda T, Yamaguchi K. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337 to Thr and Arg-388 to His). Blood 1992; 80: 2275-2280
  • 21 Miyata T, Morita T, Inomoto T, Kawauchi S, Shirakami A, Iwanaga S. Prothrombin Tokushima, a replacement of arginine-418 by tryptophan that impairs the fibrinogen clotting activity of derived thrombin Tokushima. Biochemistry 1997; 26: 1117-1122
  • 22 Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M. Molecular and genetic analysis of a compound heterozygote for dyspro- thrombinemia of Prothrombin Tokushima and hypoprothrombinemia. Am J Hum Genet 1992; 51: 1386-1395
  • 23 Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M. Detection of a single base substitution of the gene for prothrombin Tokushima. Int J Hematology 1992; 55: 93-100
  • 24 Gill FM, Shapiro SS, Schwartz E. Severe congenital hypoprothrombinemia. J Pediatrics 1998; 93: 264-266
  • 25 Tamary H, Surrey S, Augustine JG, Schwartz E, Rappaport EF. Molecular characterization of hypoprothrombinemia. Blood 1991; 78: 65a
  • 26 Shapiro SS, Martinez J, Holburn RR. Congenital dysprothrombinemia - an inherited structural disorder of human prothrombin. J Clin Invest 1999; 48: 2251-2259
  • 27 Huisse MG, Dreyfus M, Guillin MC. Prothrombin Clamart: prothrombin variant with defective Arg-320-Ile cleavage by factor Xa. Thromb Res 1996; 44: 11-21
  • 28 Rabiet MJ, Jandrot-Perriss M, Boissel JP, Elion J, Josso F. Thrombin Metz: characterization of the dysfunctional thrombin derived from a variant of human prothrombin. Blood 1994; 63: 927-934
  • 29 Rabiet MJ. Prothrombin Molis: a mutant prothrombin characterized by a defect in the thrombin domain. Thromb Haemost 1985; 54: 46
  • 30 Bell GI, Karam JH, Rutter WJ. Polymorphic DNA region adjacent to the 5’ end of the human insulin gene. Proc Natl Acad Sci USA 1991; 78: 5759-5763
  • 31 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1998; 239: 487-491
  • 32 Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1999; 5: 874-879
  • 33 Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1999; 86: 2766-2770
  • 34 Hayashi K. PCR-SSCP. A simple and sensitive method for detection of mutations in the genomic DNA PCR Methods Appl 1992; 1: 34-38
  • 35 Iwahana H, Yoshimoto K, Itakura M. Detection of point mutations by SSCP of PCR-amplified DNA after endonuclease digestion. BioTechniques 1992; 12: 64-65
  • 36 Iwahana H, Yoshimoto K, Itakura M. Nco IRFLP in the human prothrombin (F2) gene. Nucleic Acids Res 1991; 19: 4309
  • 37 Iwahana H, Yoshimoto K, Itakura M. Highly polymorphic region of the human prothrombin (F2) gene. Hum Genet 1992; 89: 123-124
  • 38 MacGillivray RT A, Davie EW. Characterization of bovine prothrombin mRNA and its translation product. Biochemistry 1994; 23: 1626-1634
  • 39 Dihanich M, Monard D. cDNA sequence of rat prothrombin. Nucleic Acids Res 1990; 18: 4251
  • 40 Degen SJ F, Schaefer LA, Jamison CS, Grant SG, Fitzgibbon JJ, Pai J-A, Chapman VM, Elliott RW. Characterization of the cDNA coding for mouse prothrombin and localization of the gene on mouse chromosome 2. DNA and Cell Biology 1990; 9: 487-498
  • 41 Karpatkin M, Tang Z, Meer J, Blei F, Samuels HH. Cloning and partial sequence of a cDNA for rabbit prothrombin. Thromb Res 1991; 62: 757-763
  • 42 Banfield DK, MacGillivray RT A. Partial characterization of vertebrate prothrombin cDNAs: amplification and sequence analysis of the B chain of thrombin from nine different species. Proc Natl Acad Sci USA 1992; 89: 2779-2783
  • 43 Bezeaud A, Drouet L, Soria C, Guillin M-C. Prothrombin Salakta: an abnormal prothrombin characterized by a defect in the active site of thrombin. Thromb Res 1984; 34: 507-518
  • 44 Bezeaud A, Elion J, Guillin M-C. Functional characterization of thrombin Salakta: an abnormal thrombin derived from a human prothrombin variant. Blood 1998; 71: 556-561
  • 45 Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human a-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1999; 8: 3467-3475